# 04_QA_REPORT

# Quality Assurance Report

## Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0166 |
| Population Package | PP-0166 — Intestinal Metaplasia and Gastric Cancer |
| Version | 1.0.0 |
| Review Status | PASS |

# Layer 1 — Content QA

| Criterion | Result |
|---|---|
| Single atomic clinical question | PASS |
| Scope respected | PASS |
| Definition included | PASS |
| Correa's cascade included | PASS |
| Gastric-cancer risk significance included | PASS |
| H. pylori context included | PASS |
| Atrophic-gastritis boundary maintained | PASS |
| Dysplasia relationship included | PASS |
| Endoscopic visibility/biopsy concept included | PASS |
| Patient explanation included | PASS |
| Misconceptions included | PASS |
| Individual-risk limitation included | PASS |

# Layer 2 — Clinical QA

| Criterion | Result |
|---|---|
| IM correctly described as precursor/risk condition | PASS |
| IM not equated with gastric cancer | PASS |
| Progression not presented as inevitable | PASS |
| H. pylori identified as major risk factor | PASS |
| Correa's cascade accurately represented | PASS |
| Biopsy/endoscopy limitation accurately represented | PASS |
| H. pylori eradication evidence appropriately qualified | PASS |
| Surveillance uncertainty preserved | PASS |
| No unsupported numerical risk estimate | PASS |
| No universal surveillance interval invented | PASS |
| No unsupported complete/incomplete IM algorithm | PASS |

# Layer 3 — Evidence QA

| Criterion | Result |
|---|---|
| NCI Genetics of Gastric Cancer PDQ reviewed | PASS |
| NCI Gastric Cancer Prevention PDQ reviewed | PASS |
| NCI Causes of Stomach Cancer reviewed | PASS |
| ACS Stomach Cancer reviewed | PASS |
| PP Registry reviewed | PASS |
| Gold Specification reviewed | PASS |
| Core Working Rules reviewed | PASS |
| Evidence hierarchy documented | PASS |
| Evidence matrix documented | PASS |
| Evidence gaps documented | PASS |
| Source traceability documented | PASS |

# Layer 4 — Educational QA

| Criterion | Result |
|---|---|
| Plain-language writing | PASS |
| Patient-centered framing | PASS |
| Medical terms explained | PASS |
| No alarmist language | PASS |
| No deterministic cancer claim | PASS |
| Misconceptions addressed | PASS |
| Action-oriented but non-prescriptive | PASS |
| No treatment recommendation outside scope | PASS |

# Layer 5 — Boundary / Overlap QA

### PP-0165 — Atrophic Gastritis and Gastric Cancer
Atrophic gastritis is upstream/contextual; IM is the current PP's owned condition.

**Result: PASS**

### PP-0160 — H. pylori and Gastric Cancer Prevention
H. pylori prevention remains delegated.

**Result: PASS**

### PP-0161 — H. pylori Eradication for Gastric Cancer Prevention
Eradication intervention remains delegated.

**Result: PASS**

### PP-0167 — Pernicious Anemia and Gastric Cancer
Pernicious anemia remains a supporting association, not a duplicate package.

**Result: PASS**

### PP-0169 — Gastric Adenomas and Cancer Risk
Gastric adenomas remain separate precursor conditions.

**Result: PASS**

### PP-0170–0174 — Gastric Cancer Screening
Screening and surveillance strategy remain separate.

**Result: PASS**

### PP-0177 — Endoscopic Biopsy Strategy
Biopsy technique remains delegated.

**Result: PASS**

### PP-0178 — Histopathologic Classification
Detailed pathology remains delegated.

**Result: PASS**

# Layer 6 — Safety QA

| Criterion | Result |
|---|---|
| No cancer diagnosis from IM alone | PASS |
| No inevitable-progression claim | PASS |
| No individualized risk calculation | PASS |
| No H. pylori regimen | PASS |
| No universal surveillance interval | PASS |
| No biopsy protocol invented | PASS |
| No pathology classification algorithm invented | PASS |
| No treatment recommendation outside scope | PASS |

# Layer 7 — Governance QA

| Criterion | Result |
|---|---|
| Approved Decision Batch respected | PASS |
| Gold Specification v1.0 respected | PASS |
| Source-First workflow followed | PASS |
| Adjacent overlap reviewed | PASS |
| Four Gold artifacts completed | PASS |
| Boundary included in production response | PASS |
| Boundary placed only in production response | PASS |
| Versioning complete | PASS |
| Repository-ready structure | PASS |

# Boundary

**Core =** definition of gastric intestinal metaplasia, IM as a gastric-cancer precursor/risk condition, relationship with chronic atrophic gastritis, H. pylori as the most common risk factor identified in the supplied NCI source, Correa's cascade, relationship with dysplasia, increased risk vs inevitable cancer, endoscopic visibility/biopsy context, clinical significance of an IM diagnosis; **Supporting =** other recognized IM risk factors, H. pylori eradication context, family-history context, pernicious-anemia context, high-incidence population context, individualized follow-up/surveillance concept; **Explicitly Excluded =** detailed atrophic-gastritis management, H. pylori diagnostic/eradication algorithms, detailed pernicious-anemia management, detailed biopsy mapping, histopathologic classification, complete vs incomplete IM classification when unsupported, OLGA/OLGIM staging, universal surveillance intervals, gastric-cancer screening algorithms, serum pepsinogen screening algorithms, dysplasia grading/treatment, gastric adenoma management, hereditary gastric-cancer assessment, gastric-cancer treatment, individualized absolute-risk calculation; **Delegated-to PP =** PP-0160, PP-0161, PP-0165, PP-0167, PP-0169, PP-0170, PP-0171, PP-0172, PP-0173, PP-0174, PP-0177, PP-0178, Hereditary Gastric Cancer, Gastric Cancer Treatment.

# Final Quality Decision

## PASS

PP-0166 satisfies the approved Decision Batch, Gold Population Package Specification v1.0, source-first requirement, and adjacent-package boundary requirements.

# QA Final Status

# PASS — GOLD — READY FOR INTEGRATION
